Skip to content
Companies

Autoimmunity Biologic Solutions

Gene-guided antibody therapy for autoimmune disease

Raised to date

$3.2M

of $3.2M offered across 1 Form D filing

Investors
15
Last filed
May 6, 2026

About

Autoimmunity BioSolutions (ABS) is a Houston-based, seed-stage biotech developing genetically guided immuno-corrective therapies for autoimmune disease. Its lead program is a first-in-class series of monoclonal antibodies that target soluble IL7 receptor (sIL7R) while sparing membrane-bound IL7R, aiming to reduce autoreactive T-cell expansion and reset immune homeostasis rather than broadly suppress the immune system. The approach targets patients carrying a common single-nucleotide polymorphism, present in roughly half the population, that raises circulating sIL7R and is linked to worse disease severity and poor response to standard therapies. The company was founded on research from Drs. Gaddiel Galarza-Munoz and Mariano A. Garcia-Blanco and has raised $3.1 million in seed capital led by Eos BioInnovation.

A genetically defined patient-selection strategy paired with antibodies selective for the soluble form of IL7R, intended to correct rather than suppress immune function and to serve the 30-50 percent of autoimmune patients who respond inadequately to current treatments.

Funding

  • EquityFiled May 6, 2026Form D/A
    $3.2M/ $3.2M

Product

Anti-sIL7R monoclonal antibody program

Preclinical biologic therapeutic

A preclinical, first-in-class series of monoclonal antibodies highly specific for soluble IL7 receptor (sIL7R), designed to normalize elevated sIL7R levels while leaving membrane-bound IL7R signaling intact.

  • Selective for soluble IL7R, sparing membrane-bound IL7R
  • Targets a prevalent IL7R SNP associated with 2-3x higher circulating sIL7R
  • Aims to reduce autoreactive T-cell expansion and restore immune homeostasis

Built for

Patients with autoimmune diseases such as progressive multiple sclerosis, lupus nephritis, rheumatoid arthritis and type 1 diabetes who carry the high-sIL7R genotype, reached through prescribing rheumatologists and neurologists and, in the near term, pharmaceutical partners and licensees

People on file